Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


loader
  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Multiple Sclerosis (MS) KOL Interview – UK, Southwest

    $599.00

    In this interview, a UK-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.

    March 2, 2020
    Find out more

  • SGLT-2 Pulse Survey

    $599.00

    We surveyed primary care physicians (n=10) and endocrinologists (n=10) to see how SGLT-2 inhibitors and the combo pills will be used and what the potential impact of usage with GLP-1 agonists may have.

    August 25, 2014
    Find out more

  • Post-EASL KOL Interview

    $599.00

    Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

    May 29, 2015
    Find out more

  • Datamonitor Schizophrenia KOL Interview

    $599.00

    On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

    February 10, 2016
    Find out more

  • Ebola KOL Interview #1

    $599.00

    So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

    November 2, 2014
    Find out more

  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

    $599.00

    This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.

    February 6, 2019
    Find out more

  • Treatment of VTE – US KOL Interview

    $599.00

    This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

    November 2, 2015
    Find out more

  • 2014 Community-Acquired Pneumonia Pulse

    $599.00

    We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.

    December 18, 2014
    Find out more

  • Non-Small Cell Lung Cancer KOL Interview – NH, US

    $1,099.00

    Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

    August 30, 2018
    Find out more

  • Ulcerative Colitis (UC) KOL Interview – UK

    $599.00

    A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

    March 1, 2021
    Find out more

  • Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

    April 1, 2020
    Find out more

  • Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

    $599.00

    An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

    November 12, 2018
    Find out more

  • Ebola KOL Interview #3

    $599.00

    Ebola KOL Interview #3

    December 2, 2014
    Find out more

  • Triple Negative Breast Cancer KOL Interview

    $599.00

    “It [Abraxane] is so easy to give. Women tolerate it so well. It works pretty good, it doesn’t work all the time, it works pretty well, and the patients don’t get so fatigued, they don’t have side effects, they don’t need premeds, and they rarely need to be boosted for white cells decrease. Whereas in the Eribulin, you know they’re gonna be coming back. It’s a pretty easy drug to give. Patients tolerate it fairly well… I use it [Abraxane] as first line and I go back to it. Even if I have somebody that progresses, if they’ve been off of it for a while, I will often even go back to it.”

    February 9, 2016
    Find out more

  • Palbociclib for Breast Cancer

    $89.00

    Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

    February 1, 2014
    Find out more
Page 1 of 12
Page 1 of 12123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Datamonitor Healthcare is part of Pharma intelligence Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
  • Informa PLC
  • ABOUT US
  • INVESTOR RELATIONS
  • TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726
informa
Call Back
Scroll to top